Company profile for Oncoinvent

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The company’s founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed Oncoinvent to explore and develop multiple technological avenues before selecting the company’s first lead product candidate. Oncoi...
The company’s founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed Oncoinvent to explore and develop multiple technological avenues before selecting the company’s first lead product candidate. Oncoinvent has built a Class B production and lab facility for radiopharmaceuticals. The facility received a GMP certificate from the Norwegian Medical Agency in February of 2019.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Norway
Address
Address
Gullhaugveien 7 0484 Oslo
Telephone
Telephone
+47 22 18 33 05
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-12-11/oncoinvent-announces-publication-of-phase-1-study-results-for-radspherin-in-ovarian-cancer-in-gynecologic-oncology

PHARMIWEB
11 Dec 2025

https://www.prnewswire.com/news-releases/oncoinvent-reports-positive-final-data-from-phase-1-trial-of-radspherin-to-treat-ovarian-cancer-302577945.html

PR NEWSWIRE
08 Oct 2025

https://www.prnewswire.com/news-releases/oncoinvent-asa-half-yearly-report-strong-focus-on-financial-discipline-and-advancing-phase-2-program-in-ovarian-cancer-302539752.html

PR NEWSWIRE
27 Aug 2025

https://www.prnewswire.com/news-releases/bergenbio-and-oncoinvent-a-rising-innovator-in-radiopharmaceutical-cancer-therapies-announce-proposed-merger-and-a-fully-underwritten-rights-issue-302494915.html

PR NEWSWIRE
30 Jun 2025

https://www.prnewswire.com/news-releases/oncoinvent-announces-positive-final-data-from-phase-12a-trial-of-radspherin-in-patients-with-colorectal-peritoneal-metastases-302484870.html

PR NEWSWIRE
18 Jun 2025

https://www.businesswire.com/news/home/20250226538555/en

BUSINESSWIRE
26 Feb 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty